Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01146561 · ClinicalTrials.gov registry record · Phase 2
Safety And Efficacy Of Tanezumab In Patients With Chronic Pancreatitis
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01146561: Clinical Trial Phase 2 study, sponsored by Pfizer.
NCT01146561 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01146561, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Tanezumab is effective in reducing the pain associated with chronic pancreatitis.
Primary Outcome
Daily average chronic pancreatitis pain is assessed with an 11-point Numeric Rating Scale (NRS) ranging from 0 (no pain) to 10 (worst possible pain).
Interventions
- OTHER Placebo
- BIOLOGICAL Tanezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2010-10-13 |
| Est. Completion | 2011-03-22 |
| Phase | Phase 2 |
Why NCT01146561 stopped before completion
NCT01146561 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01146561 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01146561 about?
NCT01146561 is a clinical study titled "Safety And Efficacy Of Tanezumab In Patients With Chronic Pancreatitis". Tanezumab is effective in reducing the pain associated with chronic pancreatitis.
What is the current status of trial NCT01146561?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2010-10-13. Estimated completion is 2011-03-22.
What interventions are being tested in trial NCT01146561?
The interventions under investigation include: Placebo (OTHER), Tanezumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01146561?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01146561's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI